Inhibidores del sistema renina-angiotensina en pacientes con covid-19.

Abstract

There is currently considerable controversy surrounding the use of renin-angiotensin system inhibitors in patients with COVID-19. Therefore, the objective of this study is to evaluate the effects of using renin-angiotensin system inhibitors in patients with COVID-19. To conduct this research, a systematic review of articles and original studies from a database such as PubMed and academic search engines such as Google Academic and Cochrane, with publication dates between 2000 and 2022 in English and Spanish, was conducted. Studies were restricted to pregnant women, children, and patients using other antihypertensive therapies. To verify the quality of the studies, the PRISMA standard was followed, and a flowchart was created of the information received and discarded, reviewing the abstracts and studies in which the participants were included. The authors concluded that the authors were of legal age and were using an ACEI/ARB during their treatment for SARS-CoV-2. Four original articles and 10 studies were selected that evaluated the clinical outcomes of patients using an ACEI-ARB sequentially with COVID-19 therapy. Finally, most studies agreed that the use of ACEI-ARB was not associated with worse clinical outcomes or higher mortality in patients with COVID-19.